0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative

0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global Radiopharmaceutical (Oral Route) Market Research Report 2025
Published Date: July 2025
|
Report Code: QYRE-Auto-23R9952
Home | Market Reports | Health| Pharmacy
Global Radiopharmaceutical Oral Route Market Insights Forecast to 2028
BUY CHAPTERS

Global Radiopharmaceutical (Oral Route) Market Research Report 2025

Code: QYRE-Auto-23R9952
Report
July 2025
Pages:95
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES

Radiopharmaceutical (Oral Route) Market Size

The global market for Radiopharmaceutical (Oral Route) was valued at US$ 7244 million in the year 2024 and is projected to reach a revised size of US$ 9433 million by 2031, growing at a CAGR of 3.9% during the forecast period.

Radiopharmaceutical (Oral Route) Market

Radiopharmaceutical (Oral Route) Market

The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Radiopharmaceutical (Oral Route), with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Radiopharmaceutical (Oral Route).
The Radiopharmaceutical (Oral Route) market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Radiopharmaceutical (Oral Route) market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Radiopharmaceutical (Oral Route) manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Scope of Radiopharmaceutical (Oral Route) Market Report

Report Metric Details
Report Name Radiopharmaceutical (Oral Route) Market
Accounted market size in year US$ 7244 million
Forecasted market size in 2031 US$ 9433 million
CAGR 3.9%
Base Year year
Forecasted years 2025 - 2031
Segment by Type
  • Actinium-225
  • Lutetium-177
  • Radium-223
  • Holmium-166
  • Other
Segment by Application
  • Oncology
  • Cardiology
  • Other
Consumption by Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia)
  • Asia-Pacific (China, Japan, South Korea, Taiwan)
  • Southeast Asia (India)
  • Latin America (Mexico, Brazil)
By Company Bracco Imaging, Bayer, Mallinckrodt, Nordion, Triad Isotopes, Lantheus, IBA Group, GE Healthcare, China Isotope & Radiation, Jubilant Pharma, Eli Lilly, Advanced Accelerator Applications, SIEMENS, Dongcheng, Navidea
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Core Chapters

  • Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
  • Chapter 2: Detailed analysis of Radiopharmaceutical (Oral Route) manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
  • Chapter 3: Sales, revenue of Radiopharmaceutical (Oral Route) in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
  • Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
  • Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
  • Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
  • Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
  • Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
  • Chapter 9: The main points and conclusions of the report. 

FAQ for this report

How fast is Radiopharmaceutical (Oral Route) Market growing?

Ans: The Radiopharmaceutical (Oral Route) Market witnessing a CAGR of 3.9% during the forecast period 2025-2031.

What is the Radiopharmaceutical (Oral Route) Market size in 2031?

Ans: The Radiopharmaceutical (Oral Route) Market size in 2031 will be US$ 9433 million.

Who are the main players in the Radiopharmaceutical (Oral Route) Market report?

Ans: The main players in the Radiopharmaceutical (Oral Route) Market are Bracco Imaging, Bayer, Mallinckrodt, Nordion, Triad Isotopes, Lantheus, IBA Group, GE Healthcare, China Isotope & Radiation, Jubilant Pharma, Eli Lilly, Advanced Accelerator Applications, SIEMENS, Dongcheng, Navidea

What are the Application segmentation covered in the Radiopharmaceutical (Oral Route) Market report?

Ans: The Applications covered in the Radiopharmaceutical (Oral Route) Market report are Oncology, Cardiology, Other

What are the Type segmentation covered in the Radiopharmaceutical (Oral Route) Market report?

Ans: The Types covered in the Radiopharmaceutical (Oral Route) Market report are Actinium-225, Lutetium-177, Radium-223, Holmium-166, Other

Recommended Reports

Oral Drug Markets

Oncology & Radiopharma

Dental & Guided Therapy

1 Radiopharmaceutical (Oral Route) Market Overview
1.1 Product Definition
1.2 Radiopharmaceutical (Oral Route) by Type
1.2.1 Global Radiopharmaceutical (Oral Route) Market Value Comparison by Type (2024 VS 2031)
1.2.2 Actinium-225
1.2.3 Lutetium-177
1.2.4 Radium-223
1.2.5 Holmium-166
1.2.6 Other
1.3 Radiopharmaceutical (Oral Route) by Application
1.3.1 Global Radiopharmaceutical (Oral Route) Market Value by Application (2024 VS 2031)
1.3.2 Oncology
1.3.3 Cardiology
1.3.4 Other
1.4 Global Radiopharmaceutical (Oral Route) Market Size Estimates and Forecasts
1.4.1 Global Radiopharmaceutical (Oral Route) Revenue 2020-2031
1.4.2 Global Radiopharmaceutical (Oral Route) Sales 2020-2031
1.4.3 Global Radiopharmaceutical (Oral Route) Market Average Price (2020-2031)
1.5 Assumptions and Limitations
2 Radiopharmaceutical (Oral Route) Market Competition by Manufacturers
2.1 Global Radiopharmaceutical (Oral Route) Sales Market Share by Manufacturers (2020-2025)
2.2 Global Radiopharmaceutical (Oral Route) Revenue Market Share by Manufacturers (2020-2025)
2.3 Global Radiopharmaceutical (Oral Route) Average Price by Manufacturers (2020-2025)
2.4 Global Key Players of Radiopharmaceutical (Oral Route), Industry Ranking, 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Radiopharmaceutical (Oral Route), Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Radiopharmaceutical (Oral Route), Product Type & Application
2.7 Global Key Manufacturers of Radiopharmaceutical (Oral Route), Date of Enter into This Industry
2.8 Global Radiopharmaceutical (Oral Route) Market Competitive Situation and Trends
2.8.1 Global Radiopharmaceutical (Oral Route) Market Concentration Rate
2.8.2 The Global 5 and 10 Largest Radiopharmaceutical (Oral Route) Players Market Share by Revenue
2.8.3 Global Radiopharmaceutical (Oral Route) Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
2.9 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Global Radiopharmaceutical (Oral Route) Market Scenario by Region
3.1 Global Radiopharmaceutical (Oral Route) Market Size by Region: 2020 Versus 2024 Versus 2031
3.2 Global Radiopharmaceutical (Oral Route) Sales by Region: 2020-2031
3.2.1 Global Radiopharmaceutical (Oral Route) Sales by Region: 2020-2025
3.2.2 Global Radiopharmaceutical (Oral Route) Sales by Region: 2026-2031
3.3 Global Radiopharmaceutical (Oral Route) Revenue by Region: 2020-2031
3.3.1 Global Radiopharmaceutical (Oral Route) Revenue by Region: 2020-2025
3.3.2 Global Radiopharmaceutical (Oral Route) Revenue by Region: 2026-2031
3.4 North America Radiopharmaceutical (Oral Route) Market Facts & Figures by Country
3.4.1 North America Radiopharmaceutical (Oral Route) Market Size by Country: 2020 VS 2024 VS 2031
3.4.2 North America Radiopharmaceutical (Oral Route) Sales by Country (2020-2031)
3.4.3 North America Radiopharmaceutical (Oral Route) Revenue by Country (2020-2031)
3.4.4 United States
3.4.5 Canada
3.5 Europe Radiopharmaceutical (Oral Route) Market Facts & Figures by Country
3.5.1 Europe Radiopharmaceutical (Oral Route) Market Size by Country: 2020 VS 2024 VS 2031
3.5.2 Europe Radiopharmaceutical (Oral Route) Sales by Country (2020-2031)
3.5.3 Europe Radiopharmaceutical (Oral Route) Revenue by Country (2020-2031)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Radiopharmaceutical (Oral Route) Market Facts & Figures by Region
3.6.1 Asia Pacific Radiopharmaceutical (Oral Route) Market Size by Region: 2020 VS 2024 VS 2031
3.6.2 Asia Pacific Radiopharmaceutical (Oral Route) Sales by Region (2020-2031)
3.6.3 Asia Pacific Radiopharmaceutical (Oral Route) Revenue by Region (2020-2031)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.7 Latin America Radiopharmaceutical (Oral Route) Market Facts & Figures by Country
3.7.1 Latin America Radiopharmaceutical (Oral Route) Market Size by Country: 2020 VS 2024 VS 2031
3.7.2 Latin America Radiopharmaceutical (Oral Route) Sales by Country (2020-2031)
3.7.3 Latin America Radiopharmaceutical (Oral Route) Revenue by Country (2020-2031)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Radiopharmaceutical (Oral Route) Market Facts & Figures by Country
3.8.1 Middle East and Africa Radiopharmaceutical (Oral Route) Market Size by Country: 2020 VS 2024 VS 2031
3.8.2 Middle East and Africa Radiopharmaceutical (Oral Route) Sales by Country (2020-2031)
3.8.3 Middle East and Africa Radiopharmaceutical (Oral Route) Revenue by Country (2020-2031)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Radiopharmaceutical (Oral Route) Sales by Type (2020-2031)
4.1.1 Global Radiopharmaceutical (Oral Route) Sales by Type (2020-2025)
4.1.2 Global Radiopharmaceutical (Oral Route) Sales by Type (2026-2031)
4.1.3 Global Radiopharmaceutical (Oral Route) Sales Market Share by Type (2020-2031)
4.2 Global Radiopharmaceutical (Oral Route) Revenue by Type (2020-2031)
4.2.1 Global Radiopharmaceutical (Oral Route) Revenue by Type (2020-2025)
4.2.2 Global Radiopharmaceutical (Oral Route) Revenue by Type (2026-2031)
4.2.3 Global Radiopharmaceutical (Oral Route) Revenue Market Share by Type (2020-2031)
4.3 Global Radiopharmaceutical (Oral Route) Price by Type (2020-2031)
5 Segment by Application
5.1 Global Radiopharmaceutical (Oral Route) Sales by Application (2020-2031)
5.1.1 Global Radiopharmaceutical (Oral Route) Sales by Application (2020-2025)
5.1.2 Global Radiopharmaceutical (Oral Route) Sales by Application (2026-2031)
5.1.3 Global Radiopharmaceutical (Oral Route) Sales Market Share by Application (2020-2031)
5.2 Global Radiopharmaceutical (Oral Route) Revenue by Application (2020-2031)
5.2.1 Global Radiopharmaceutical (Oral Route) Revenue by Application (2020-2025)
5.2.2 Global Radiopharmaceutical (Oral Route) Revenue by Application (2026-2031)
5.2.3 Global Radiopharmaceutical (Oral Route) Revenue Market Share by Application (2020-2031)
5.3 Global Radiopharmaceutical (Oral Route) Price by Application (2020-2031)
6 Key Companies Profiled
6.1 Bracco Imaging
6.1.1 Bracco Imaging Company Information
6.1.2 Bracco Imaging Description and Business Overview
6.1.3 Bracco Imaging Radiopharmaceutical (Oral Route) Sales, Revenue and Gross Margin (2020-2025)
6.1.4 Bracco Imaging Radiopharmaceutical (Oral Route) Product Portfolio
6.1.5 Bracco Imaging Recent Developments/Updates
6.2 Bayer
6.2.1 Bayer Company Information
6.2.2 Bayer Description and Business Overview
6.2.3 Bayer Radiopharmaceutical (Oral Route) Sales, Revenue and Gross Margin (2020-2025)
6.2.4 Bayer Radiopharmaceutical (Oral Route) Product Portfolio
6.2.5 Bayer Recent Developments/Updates
6.3 Mallinckrodt
6.3.1 Mallinckrodt Company Information
6.3.2 Mallinckrodt Description and Business Overview
6.3.3 Mallinckrodt Radiopharmaceutical (Oral Route) Sales, Revenue and Gross Margin (2020-2025)
6.3.4 Mallinckrodt Radiopharmaceutical (Oral Route) Product Portfolio
6.3.5 Mallinckrodt Recent Developments/Updates
6.4 Nordion
6.4.1 Nordion Company Information
6.4.2 Nordion Description and Business Overview
6.4.3 Nordion Radiopharmaceutical (Oral Route) Sales, Revenue and Gross Margin (2020-2025)
6.4.4 Nordion Radiopharmaceutical (Oral Route) Product Portfolio
6.4.5 Nordion Recent Developments/Updates
6.5 Triad Isotopes
6.5.1 Triad Isotopes Company Information
6.5.2 Triad Isotopes Description and Business Overview
6.5.3 Triad Isotopes Radiopharmaceutical (Oral Route) Sales, Revenue and Gross Margin (2020-2025)
6.5.4 Triad Isotopes Radiopharmaceutical (Oral Route) Product Portfolio
6.5.5 Triad Isotopes Recent Developments/Updates
6.6 Lantheus
6.6.1 Lantheus Company Information
6.6.2 Lantheus Description and Business Overview
6.6.3 Lantheus Radiopharmaceutical (Oral Route) Sales, Revenue and Gross Margin (2020-2025)
6.6.4 Lantheus Radiopharmaceutical (Oral Route) Product Portfolio
6.6.5 Lantheus Recent Developments/Updates
6.7 IBA Group
6.7.1 IBA Group Company Information
6.7.2 IBA Group Description and Business Overview
6.7.3 IBA Group Radiopharmaceutical (Oral Route) Sales, Revenue and Gross Margin (2020-2025)
6.7.4 IBA Group Radiopharmaceutical (Oral Route) Product Portfolio
6.7.5 IBA Group Recent Developments/Updates
6.8 GE Healthcare
6.8.1 GE Healthcare Company Information
6.8.2 GE Healthcare Description and Business Overview
6.8.3 GE Healthcare Radiopharmaceutical (Oral Route) Sales, Revenue and Gross Margin (2020-2025)
6.8.4 GE Healthcare Radiopharmaceutical (Oral Route) Product Portfolio
6.8.5 GE Healthcare Recent Developments/Updates
6.9 China Isotope & Radiation
6.9.1 China Isotope & Radiation Company Information
6.9.2 China Isotope & Radiation Description and Business Overview
6.9.3 China Isotope & Radiation Radiopharmaceutical (Oral Route) Sales, Revenue and Gross Margin (2020-2025)
6.9.4 China Isotope & Radiation Radiopharmaceutical (Oral Route) Product Portfolio
6.9.5 China Isotope & Radiation Recent Developments/Updates
6.10 Jubilant Pharma
6.10.1 Jubilant Pharma Company Information
6.10.2 Jubilant Pharma Description and Business Overview
6.10.3 Jubilant Pharma Radiopharmaceutical (Oral Route) Sales, Revenue and Gross Margin (2020-2025)
6.10.4 Jubilant Pharma Radiopharmaceutical (Oral Route) Product Portfolio
6.10.5 Jubilant Pharma Recent Developments/Updates
6.11 Eli Lilly
6.11.1 Eli Lilly Company Information
6.11.2 Eli Lilly Description and Business Overview
6.11.3 Eli Lilly Radiopharmaceutical (Oral Route) Sales, Revenue and Gross Margin (2020-2025)
6.11.4 Eli Lilly Radiopharmaceutical (Oral Route) Product Portfolio
6.11.5 Eli Lilly Recent Developments/Updates
6.12 Advanced Accelerator Applications
6.12.1 Advanced Accelerator Applications Company Information
6.12.2 Advanced Accelerator Applications Description and Business Overview
6.12.3 Advanced Accelerator Applications Radiopharmaceutical (Oral Route) Sales, Revenue and Gross Margin (2020-2025)
6.12.4 Advanced Accelerator Applications Radiopharmaceutical (Oral Route) Product Portfolio
6.12.5 Advanced Accelerator Applications Recent Developments/Updates
6.13 SIEMENS
6.13.1 SIEMENS Company Information
6.13.2 SIEMENS Description and Business Overview
6.13.3 SIEMENS Radiopharmaceutical (Oral Route) Sales, Revenue and Gross Margin (2020-2025)
6.13.4 SIEMENS Radiopharmaceutical (Oral Route) Product Portfolio
6.13.5 SIEMENS Recent Developments/Updates
6.14 Dongcheng
6.14.1 Dongcheng Company Information
6.14.2 Dongcheng Description and Business Overview
6.14.3 Dongcheng Radiopharmaceutical (Oral Route) Sales, Revenue and Gross Margin (2020-2025)
6.14.4 Dongcheng Radiopharmaceutical (Oral Route) Product Portfolio
6.14.5 Dongcheng Recent Developments/Updates
6.15 Navidea
6.15.1 Navidea Company Information
6.15.2 Navidea Description and Business Overview
6.15.3 Navidea Radiopharmaceutical (Oral Route) Sales, Revenue and Gross Margin (2020-2025)
6.15.4 Navidea Radiopharmaceutical (Oral Route) Product Portfolio
6.15.5 Navidea Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Radiopharmaceutical (Oral Route) Industry Chain Analysis
7.2 Radiopharmaceutical (Oral Route) Raw Material Supply Analysis
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Radiopharmaceutical (Oral Route) Production Mode & Process Analysis
7.4 Radiopharmaceutical (Oral Route) Sales and Marketing
7.4.1 Radiopharmaceutical (Oral Route) Sales Channels
7.4.2 Radiopharmaceutical (Oral Route) Distributors
7.5 Radiopharmaceutical (Oral Route) Customer Analysis
8 Radiopharmaceutical (Oral Route) Market Dynamics
8.1 Radiopharmaceutical (Oral Route) Industry Trends
8.2 Radiopharmaceutical (Oral Route) Market Drivers
8.3 Radiopharmaceutical (Oral Route) Market Challenges
8.4 Radiopharmaceutical (Oral Route) Market Restraints
9 Research Findings and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
List of Tables
 Table 1. Global Radiopharmaceutical (Oral Route) Market Value Comparison by Type (2024 VS 2031) & (US$ Million)
 Table 2. Global Radiopharmaceutical (Oral Route) Market Value by Application (2024 VS 2031) & (US$ Million)
 Table 3. Global Radiopharmaceutical (Oral Route) Market Competitive Situation by Manufacturers in 2024
 Table 4. Global Radiopharmaceutical (Oral Route) Sales (K Units) of Key Manufacturers (2020-2025)
 Table 5. Global Radiopharmaceutical (Oral Route) Sales Market Share by Manufacturers (2020-2025)
 Table 6. Global Radiopharmaceutical (Oral Route) Revenue (US$ Million) by Manufacturers (2020-2025)
 Table 7. Global Radiopharmaceutical (Oral Route) Revenue Share by Manufacturers (2020-2025)
 Table 8. Global Market Radiopharmaceutical (Oral Route) Average Price (US$/Unit) of Key Manufacturers (2020-2025)
 Table 9. Global Key Players of Radiopharmaceutical (Oral Route), Industry Ranking, 2022 VS 2023 VS 2024
 Table 10. Global Key Manufacturers of Radiopharmaceutical (Oral Route), Manufacturing Sites & Headquarters
 Table 11. Global Key Manufacturers of Radiopharmaceutical (Oral Route), Product Type & Application
 Table 12. Global Key Manufacturers of Radiopharmaceutical (Oral Route), Date of Enter into This Industry
 Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
 Table 14. Global Radiopharmaceutical (Oral Route) by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Radiopharmaceutical (Oral Route) as of 2024)
 Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
 Table 16. Global Radiopharmaceutical (Oral Route) Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
 Table 17. Global Radiopharmaceutical (Oral Route) Sales by Region (2020-2025) & (K Units)
 Table 18. Global Radiopharmaceutical (Oral Route) Sales Market Share by Region (2020-2025)
 Table 19. Global Radiopharmaceutical (Oral Route) Sales by Region (2026-2031) & (K Units)
 Table 20. Global Radiopharmaceutical (Oral Route) Sales Market Share by Region (2026-2031)
 Table 21. Global Radiopharmaceutical (Oral Route) Revenue by Region (2020-2025) & (US$ Million)
 Table 22. Global Radiopharmaceutical (Oral Route) Revenue Market Share by Region (2020-2025)
 Table 23. Global Radiopharmaceutical (Oral Route) Revenue by Region (2026-2031) & (US$ Million)
 Table 24. Global Radiopharmaceutical (Oral Route) Revenue Market Share by Region (2026-2031)
 Table 25. North America Radiopharmaceutical (Oral Route) Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 26. North America Radiopharmaceutical (Oral Route) Sales by Country (2020-2025) & (K Units)
 Table 27. North America Radiopharmaceutical (Oral Route) Sales by Country (2026-2031) & (K Units)
 Table 28. North America Radiopharmaceutical (Oral Route) Revenue by Country (2020-2025) & (US$ Million)
 Table 29. North America Radiopharmaceutical (Oral Route) Revenue by Country (2026-2031) & (US$ Million)
 Table 30. Europe Radiopharmaceutical (Oral Route) Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 31. Europe Radiopharmaceutical (Oral Route) Sales by Country (2020-2025) & (K Units)
 Table 32. Europe Radiopharmaceutical (Oral Route) Sales by Country (2026-2031) & (K Units)
 Table 33. Europe Radiopharmaceutical (Oral Route) Revenue by Country (2020-2025) & (US$ Million)
 Table 34. Europe Radiopharmaceutical (Oral Route) Revenue by Country (2026-2031) & (US$ Million)
 Table 35. Asia Pacific Radiopharmaceutical (Oral Route) Revenue by Region: 2020 VS 2024 VS 2031 (US$ Million)
 Table 36. Asia Pacific Radiopharmaceutical (Oral Route) Sales by Region (2020-2025) & (K Units)
 Table 37. Asia Pacific Radiopharmaceutical (Oral Route) Sales by Region (2026-2031) & (K Units)
 Table 38. Asia Pacific Radiopharmaceutical (Oral Route) Revenue by Region (2020-2025) & (US$ Million)
 Table 39. Asia Pacific Radiopharmaceutical (Oral Route) Revenue by Region (2026-2031) & (US$ Million)
 Table 40. Latin America Radiopharmaceutical (Oral Route) Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 41. Latin America Radiopharmaceutical (Oral Route) Sales by Country (2020-2025) & (K Units)
 Table 42. Latin America Radiopharmaceutical (Oral Route) Sales by Country (2026-2031) & (K Units)
 Table 43. Latin America Radiopharmaceutical (Oral Route) Revenue by Country (2020-2025) & (US$ Million)
 Table 44. Latin America Radiopharmaceutical (Oral Route) Revenue by Country (2026-2031) & (US$ Million)
 Table 45. Middle East and Africa Radiopharmaceutical (Oral Route) Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 46. Middle East and Africa Radiopharmaceutical (Oral Route) Sales by Country (2020-2025) & (K Units)
 Table 47. Middle East and Africa Radiopharmaceutical (Oral Route) Sales by Country (2026-2031) & (K Units)
 Table 48. Middle East and Africa Radiopharmaceutical (Oral Route) Revenue by Country (2020-2025) & (US$ Million)
 Table 49. Middle East and Africa Radiopharmaceutical (Oral Route) Revenue by Country (2026-2031) & (US$ Million)
 Table 50. Global Radiopharmaceutical (Oral Route) Sales (K Units) by Type (2020-2025)
 Table 51. Global Radiopharmaceutical (Oral Route) Sales (K Units) by Type (2026-2031)
 Table 52. Global Radiopharmaceutical (Oral Route) Sales Market Share by Type (2020-2025)
 Table 53. Global Radiopharmaceutical (Oral Route) Sales Market Share by Type (2026-2031)
 Table 54. Global Radiopharmaceutical (Oral Route) Revenue (US$ Million) by Type (2020-2025)
 Table 55. Global Radiopharmaceutical (Oral Route) Revenue (US$ Million) by Type (2026-2031)
 Table 56. Global Radiopharmaceutical (Oral Route) Revenue Market Share by Type (2020-2025)
 Table 57. Global Radiopharmaceutical (Oral Route) Revenue Market Share by Type (2026-2031)
 Table 58. Global Radiopharmaceutical (Oral Route) Price (US$/Unit) by Type (2020-2025)
 Table 59. Global Radiopharmaceutical (Oral Route) Price (US$/Unit) by Type (2026-2031)
 Table 60. Global Radiopharmaceutical (Oral Route) Sales (K Units) by Application (2020-2025)
 Table 61. Global Radiopharmaceutical (Oral Route) Sales (K Units) by Application (2026-2031)
 Table 62. Global Radiopharmaceutical (Oral Route) Sales Market Share by Application (2020-2025)
 Table 63. Global Radiopharmaceutical (Oral Route) Sales Market Share by Application (2026-2031)
 Table 64. Global Radiopharmaceutical (Oral Route) Revenue (US$ Million) by Application (2020-2025)
 Table 65. Global Radiopharmaceutical (Oral Route) Revenue (US$ Million) by Application (2026-2031)
 Table 66. Global Radiopharmaceutical (Oral Route) Revenue Market Share by Application (2020-2025)
 Table 67. Global Radiopharmaceutical (Oral Route) Revenue Market Share by Application (2026-2031)
 Table 68. Global Radiopharmaceutical (Oral Route) Price (US$/Unit) by Application (2020-2025)
 Table 69. Global Radiopharmaceutical (Oral Route) Price (US$/Unit) by Application (2026-2031)
 Table 70. Bracco Imaging Company Information
 Table 71. Bracco Imaging Description and Business Overview
 Table 72. Bracco Imaging Radiopharmaceutical (Oral Route) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 73. Bracco Imaging Radiopharmaceutical (Oral Route) Product
 Table 74. Bracco Imaging Recent Developments/Updates
 Table 75. Bayer Company Information
 Table 76. Bayer Description and Business Overview
 Table 77. Bayer Radiopharmaceutical (Oral Route) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 78. Bayer Radiopharmaceutical (Oral Route) Product
 Table 79. Bayer Recent Developments/Updates
 Table 80. Mallinckrodt Company Information
 Table 81. Mallinckrodt Description and Business Overview
 Table 82. Mallinckrodt Radiopharmaceutical (Oral Route) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 83. Mallinckrodt Radiopharmaceutical (Oral Route) Product
 Table 84. Mallinckrodt Recent Developments/Updates
 Table 85. Nordion Company Information
 Table 86. Nordion Description and Business Overview
 Table 87. Nordion Radiopharmaceutical (Oral Route) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 88. Nordion Radiopharmaceutical (Oral Route) Product
 Table 89. Nordion Recent Developments/Updates
 Table 90. Triad Isotopes Company Information
 Table 91. Triad Isotopes Description and Business Overview
 Table 92. Triad Isotopes Radiopharmaceutical (Oral Route) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 93. Triad Isotopes Radiopharmaceutical (Oral Route) Product
 Table 94. Triad Isotopes Recent Developments/Updates
 Table 95. Lantheus Company Information
 Table 96. Lantheus Description and Business Overview
 Table 97. Lantheus Radiopharmaceutical (Oral Route) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 98. Lantheus Radiopharmaceutical (Oral Route) Product
 Table 99. Lantheus Recent Developments/Updates
 Table 100. IBA Group Company Information
 Table 101. IBA Group Description and Business Overview
 Table 102. IBA Group Radiopharmaceutical (Oral Route) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 103. IBA Group Radiopharmaceutical (Oral Route) Product
 Table 104. IBA Group Recent Developments/Updates
 Table 105. GE Healthcare Company Information
 Table 106. GE Healthcare Description and Business Overview
 Table 107. GE Healthcare Radiopharmaceutical (Oral Route) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 108. GE Healthcare Radiopharmaceutical (Oral Route) Product
 Table 109. GE Healthcare Recent Developments/Updates
 Table 110. China Isotope & Radiation Company Information
 Table 111. China Isotope & Radiation Description and Business Overview
 Table 112. China Isotope & Radiation Radiopharmaceutical (Oral Route) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 113. China Isotope & Radiation Radiopharmaceutical (Oral Route) Product
 Table 114. China Isotope & Radiation Recent Developments/Updates
 Table 115. Jubilant Pharma Company Information
 Table 116. Jubilant Pharma Description and Business Overview
 Table 117. Jubilant Pharma Radiopharmaceutical (Oral Route) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 118. Jubilant Pharma Radiopharmaceutical (Oral Route) Product
 Table 119. Jubilant Pharma Recent Developments/Updates
 Table 120. Eli Lilly Company Information
 Table 121. Eli Lilly Description and Business Overview
 Table 122. Eli Lilly Radiopharmaceutical (Oral Route) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 123. Eli Lilly Radiopharmaceutical (Oral Route) Product
 Table 124. Eli Lilly Recent Developments/Updates
 Table 125. Advanced Accelerator Applications Company Information
 Table 126. Advanced Accelerator Applications Description and Business Overview
 Table 127. Advanced Accelerator Applications Radiopharmaceutical (Oral Route) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 128. Advanced Accelerator Applications Radiopharmaceutical (Oral Route) Product
 Table 129. Advanced Accelerator Applications Recent Developments/Updates
 Table 130. SIEMENS Company Information
 Table 131. SIEMENS Description and Business Overview
 Table 132. SIEMENS Radiopharmaceutical (Oral Route) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 133. SIEMENS Radiopharmaceutical (Oral Route) Product
 Table 134. SIEMENS Recent Developments/Updates
 Table 135. Dongcheng Company Information
 Table 136. Dongcheng Description and Business Overview
 Table 137. Dongcheng Radiopharmaceutical (Oral Route) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 138. Dongcheng Radiopharmaceutical (Oral Route) Product
 Table 139. Dongcheng Recent Developments/Updates
 Table 140. Navidea Company Information
 Table 141. Navidea Description and Business Overview
 Table 142. Navidea Radiopharmaceutical (Oral Route) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 143. Navidea Radiopharmaceutical (Oral Route) Product
 Table 144. Navidea Recent Developments/Updates
 Table 145. Key Raw Materials Lists
 Table 146. Raw Materials Key Suppliers Lists
 Table 147. Radiopharmaceutical (Oral Route) Distributors List
 Table 148. Radiopharmaceutical (Oral Route) Customers List
 Table 149. Radiopharmaceutical (Oral Route) Market Trends
 Table 150. Radiopharmaceutical (Oral Route) Market Drivers
 Table 151. Radiopharmaceutical (Oral Route) Market Challenges
 Table 152. Radiopharmaceutical (Oral Route) Market Restraints
 Table 153. Research Programs/Design for This Report
 Table 154. Key Data Information from Secondary Sources
 Table 155. Key Data Information from Primary Sources
 Table 156. Authors List of This Report


List of Figures
 Figure 1. Product Picture of Radiopharmaceutical (Oral Route)
 Figure 2. Global Radiopharmaceutical (Oral Route) Market Value Comparison by Type (2020-2031) & (US$ Million)
 Figure 3. Global Radiopharmaceutical (Oral Route) Market Share by Type: 2024 & 2031
 Figure 4. Actinium-225 Product Picture
 Figure 5. Lutetium-177 Product Picture
 Figure 6. Radium-223 Product Picture
 Figure 7. Holmium-166 Product Picture
 Figure 8. Other Product Picture
 Figure 9. Global Radiopharmaceutical (Oral Route) Market Value by Application (2020-2031) & (US$ Million)
 Figure 10. Global Radiopharmaceutical (Oral Route) Market Share by Application: 2024 & 2031
 Figure 11. Oncology
 Figure 12. Cardiology
 Figure 13. Other
 Figure 14. Global Radiopharmaceutical (Oral Route) Revenue, (US$ Million), 2020 VS 2024 VS 2031
 Figure 15. Global Radiopharmaceutical (Oral Route) Market Size (2020-2031) & (US$ Million)
 Figure 16. Global Radiopharmaceutical (Oral Route) Sales (2020-2031) & (K Units)
 Figure 17. Global Radiopharmaceutical (Oral Route) Average Price (US$/Unit) & (2020-2031)
 Figure 18. Radiopharmaceutical (Oral Route) Report Years Considered
 Figure 19. Radiopharmaceutical (Oral Route) Sales Share by Manufacturers in 2024
 Figure 20. Global Radiopharmaceutical (Oral Route) Revenue Share by Manufacturers in 2024
 Figure 21. Global 5 and 10 Largest Radiopharmaceutical (Oral Route) Players: Market Share by Revenue in Radiopharmaceutical (Oral Route) in 2024
 Figure 22. Radiopharmaceutical (Oral Route) Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024
 Figure 23. Global Radiopharmaceutical (Oral Route) Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
 Figure 24. North America Radiopharmaceutical (Oral Route) Sales Market Share by Country (2020-2031)
 Figure 25. North America Radiopharmaceutical (Oral Route) Revenue Market Share by Country (2020-2031)
 Figure 26. United States Radiopharmaceutical (Oral Route) Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 27. Canada Radiopharmaceutical (Oral Route) Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 28. Europe Radiopharmaceutical (Oral Route) Sales Market Share by Country (2020-2031)
 Figure 29. Europe Radiopharmaceutical (Oral Route) Revenue Market Share by Country (2020-2031)
 Figure 30. Germany Radiopharmaceutical (Oral Route) Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 31. France Radiopharmaceutical (Oral Route) Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 32. U.K. Radiopharmaceutical (Oral Route) Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 33. Italy Radiopharmaceutical (Oral Route) Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 34. Russia Radiopharmaceutical (Oral Route) Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 35. Asia Pacific Radiopharmaceutical (Oral Route) Sales Market Share by Region (2020-2031)
 Figure 36. Asia Pacific Radiopharmaceutical (Oral Route) Revenue Market Share by Region (2020-2031)
 Figure 37. China Radiopharmaceutical (Oral Route) Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 38. Japan Radiopharmaceutical (Oral Route) Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 39. South Korea Radiopharmaceutical (Oral Route) Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 40. India Radiopharmaceutical (Oral Route) Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 41. Australia Radiopharmaceutical (Oral Route) Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 42. China Taiwan Radiopharmaceutical (Oral Route) Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 43. Indonesia Radiopharmaceutical (Oral Route) Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 44. Thailand Radiopharmaceutical (Oral Route) Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 45. Malaysia Radiopharmaceutical (Oral Route) Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 46. Latin America Radiopharmaceutical (Oral Route) Sales Market Share by Country (2020-2031)
 Figure 47. Latin America Radiopharmaceutical (Oral Route) Revenue Market Share by Country (2020-2031)
 Figure 48. Mexico Radiopharmaceutical (Oral Route) Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 49. Brazil Radiopharmaceutical (Oral Route) Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 50. Argentina Radiopharmaceutical (Oral Route) Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 51. Middle East and Africa Radiopharmaceutical (Oral Route) Sales Market Share by Country (2020-2031)
 Figure 52. Middle East and Africa Radiopharmaceutical (Oral Route) Revenue Market Share by Country (2020-2031)
 Figure 53. Turkey Radiopharmaceutical (Oral Route) Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 54. Saudi Arabia Radiopharmaceutical (Oral Route) Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 55. UAE Radiopharmaceutical (Oral Route) Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 56. Global Sales Market Share of Radiopharmaceutical (Oral Route) by Type (2020-2031)
 Figure 57. Global Revenue Market Share of Radiopharmaceutical (Oral Route) by Type (2020-2031)
 Figure 58. Global Radiopharmaceutical (Oral Route) Price (US$/Unit) by Type (2020-2031)
 Figure 59. Global Sales Market Share of Radiopharmaceutical (Oral Route) by Application (2020-2031)
 Figure 60. Global Revenue Market Share of Radiopharmaceutical (Oral Route) by Application (2020-2031)
 Figure 61. Global Radiopharmaceutical (Oral Route) Price (US$/Unit) by Application (2020-2031)
 Figure 62. Radiopharmaceutical (Oral Route) Value Chain
 Figure 63. Channels of Distribution (Direct Vs Distribution)
 Figure 64. Bottom-up and Top-down Approaches for This Report
 Figure 65. Data Triangulation
 Figure 66. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic (PDF)

$2900

This license allows only one user to access the PDF.
Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together
Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report
Add to Cart
Buy Now (15% Discount)

OUR CUSTOMER

SIS Group of Schools

SIMILAR REPORTS

RELATED REPORTS

Global GLP-1 Targeted Peptide Weight Loss Drugs Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-19A18322
Fri Sep 12 00:00:00 UTC 2025

Add to Cart

Global Stimulant-Free Fat Burners Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-3E3525
Thu Sep 11 00:00:00 UTC 2025

Add to Cart

Global Test Boosters Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-35T3049
Thu Sep 11 00:00:00 UTC 2025

Add to Cart

Global Salsalate Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-33Y1801
Thu Sep 11 00:00:00 UTC 2025

Add to Cart